Asset & Pipeline Development Planning
How we help with Asset & Pipeline Development Planning
Asset & pipeline development planning is about streamlining a development strategy, highlighting efficient development pathways, and optimizing the speed and efficiency of asset development. Halloran uses an integrated, cross-functional lens to provide benchmarking, assumptions, risk analysis, and resource planning with coordinated timelines and budgets for our client’s programs. This plan is broken out by key activities and functional areas across clinical development, regulatory, chemistry manufacturing and controls (CMC), and non-clinical development.
Throughout the creation of the Asset & Pipeline Development Plan, we become our client’s trusted partner to accelerate progress and are fully prepared to lead the implementation of the plan, if desired.
Small life science companies often need to ‘do more with less.’ Leaders of these companies must seek ways to trim costs without sacrificing quality and speed. As you build your development team, you may be tempted to forgo hiring a Program Manager, but that decision may create less-than-desirable results. Leaders of life science companies, especially […]
Read our latest Case StudyTurning Drug Development Chaos into Order for an NDA Situation The average approval time often takes 10-15 years from Phase 1 to approval. The cost of drug development for sponsors ranges from $314 million to $2.8 billion. The milestone of submitting a New Drug Application (NDA) for approval by the U.S. […]
Providing Clinical Leadership for Early-Stage IO Biotechs from a Leader Who Built Her Own Clinical Support Group
This content was originally published in Women Leadership in Immuno-Oncology Issue 2023. Click here to read the original article. What does Halloran Consulting do in immuno-oncology? Our expertise is strategic program leadership, clinical development planning, regulatory affairs, and regulatory operations to early-and late-stage biotech and pharma companies with immuno-oncology assets. In some cases, we act […]